Completed PHASE2 INTERVENTIONAL NCT00045864

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Sponsor: Chiron Corporation

Interventions Recombinant Human Interleukin-2 and Rituximab

Updated 6 times since 2017 Last updated: Feb 2, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lymphoma, Non-Hodgkin and is currently completed. Chiron Corporation leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiron Corporation

Data source: Chiron Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bloomington, United States , Canton, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States , Columbus, United States , Corpus Christi, United States , Fargo, United States , Germantown, United States , Greenville, United States and 20 more locations